Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Emad Farjami & Mohammad Mahjoob. (2023) Multiscale modeling of the dynamic growth of cancerous tumors under the influence of chemotherapy drugs. Computer Methods in Biomechanics and Biomedical Engineering 0:0, pages 1-12.
Read now
Read now
Letizia Carrara, Silvia Maria Lavezzi, Elisa Borella, Giuseppe De Nicolao, Paolo Magni & Italo Poggesi. (2017) Current mathematical models for cancer drug discovery. Expert Opinion on Drug Discovery 12:8, pages 785-799.
Read now
Read now
Shinji Yamazaki, Mary E. Spilker & Paolo Vicini. (2016) Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. Expert Opinion on Drug Metabolism & Toxicology 12:3, pages 253-265.
Read now
Read now
Articles from other publishers (40)
Amirreza Khalili Golmankhaneh, Sümeyye Tunç, Agnieszka Matylda Schlichtinger, Dachel Martinez Asanza & Alireza Khalili Golmankhaneh. (2024) Modeling tumor growth using fractal calculus: Insights into tumor dynamics. Biosystems 235, pages 105071.
Crossref
Crossref
Alessandro De Carlo, Elena Maria Tosca, Nicola Melillo & Paolo Magni. (2023) A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory. Journal of Pharmacokinetics and Pharmacodynamics 50:5, pages 395-409.
Crossref
Crossref
Thi Khanh Le, Chaïma Cherif, Kenneth Omabe, Clément Paris, François Lannes, Stéphane Audebert, Emilie Baudelet, Mourad Hamimed, Dominique Barbolosi, Pascal Finetti, Cyrille Bastide, Ladan Fazli, Martin Gleave, François Bertucci, David Taïeb & Palma Rocchi. (2023) DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer. Molecular Therapy 31:2, pages 471-486.
Crossref
Crossref
Benjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, Caroline Chung, Howard Colman, Patricia E Cole, David Leung, Joshua E Allen, Manmeet S Ahluwalia, Jerrold Boxerman, Matthew Brown, Jonathan Goldin, Edjah Nduom, Islam Hassan, Mark R Gilbert, Ingo K Mellinghoff, Michael Weller, Susan Chang, David Arons, Clair Meehan, Wendy Selig, Kirk Tanner, W K Alfred Yung, Martin van den Bent, Patrick Y Wen & Timothy F Cloughesy. (2022) Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology 24:8, pages 1219-1229.
Crossref
Crossref
Mourad Hamimed, Pierre Leblond, Aurélie Dumont, Florence Gattacceca, Emmanuelle Tresch-Bruneel, Alicia Probst, Pascal Chastagner, Anne Pagnier, Emilie De Carli, Natacha Entz-Werlé, Jacques Grill, Isabelle Aerts, Didier Frappaz, Anne-Isabelle Bertozzi-Salamon, Caroline Solas, Nicolas André & Joseph Ciccolini. (2022) Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology 90:1, pages 29-44.
Crossref
Crossref
Akhtar Ali, Majid Hussain, Abdul Ghaffar, Zafar Ali, Kottakkaran Sooppy Nisar, M.R. Alharthi & Wasim Jamshed. (2021) Numerical simulations and analysis for mathematical model of avascular tumor growth using Gompertz growth rate function. Alexandria Engineering Journal 60:4, pages 3731-3740.
Crossref
Crossref
Alistair McQueen, Javier Escuer, Ankush Aggarwal, Simon Kennedy, Christopher McCormick, Keith Oldroyd & Sean McGinty. (2021) Do we really understand how drug eluted from stents modulates arterial healing?. International Journal of Pharmaceutics 601, pages 120575.
Crossref
Crossref
Clarisse Dromain, Arturo Loaiza-Bonilla, Beloo Mirakhur, Thomas J.R. Beveridge & Antonio Tito Fojo. (2021) Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. The Oncologist 26:4, pages e632-e638.
Crossref
Crossref
Rosalba Vivian Paredes Bonilla, Fahima Nekka & Morgan Craig. (2021) A Quantitative Systems Pharmacology Framework for Optimal Doxorubicin Granulocyte Colony-Stimulating Factor Regimens in Triple-Negative Breast Cancer. Pharmacology 106:9-10, pages 542-550.
Crossref
Crossref
Cristian Axenie & Daria Kurz. 2021. Machine Learning and Knowledge Discovery in Databases. Applied Data Science and Demo Track. Machine Learning and Knowledge Discovery in Databases. Applied Data Science and Demo Track
171
186
.
S.H. Sabzpoushan. (2020) A flexible nonlinear model for simulating growth systems. Communications in Nonlinear Science and Numerical Simulation 82, pages 105009.
Crossref
Crossref
Ye Yao, Qingyu Yao, Yu Fu, Xiuyun Tian, Qiming An, Liang Yang, Hong Su, Wei Lu, Chunyi Hao & Tianyan Zhou. (2020) Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Journal of Pharmaceutical Sciences 109:2, pages 1169-1177.
Crossref
Crossref
Birgit Schoeberl. (2019) Quantitative Systems Pharmacology models as a key to translational medicine. Current Opinion in Systems Biology 16, pages 25-31.
Crossref
Crossref
E. M. Tosca, M. C. Pigatto, T. Dalla Costa & P. Magni. (2019) A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats. Pharmaceutical Research 36:3.
Crossref
Crossref
David C. Turner, Anna G. Kondic, Keaven M. Anderson, Andrew G. Robinson, Edward B. Garon, Jonathan Wesley Riess, Lokesh Jain, Kapil Mayawala, Jiannan Kang, Scot W. Ebbinghaus, Vikram Sinha, Dinesh P. de Alwis & Julie A. Stone. (2018) Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clinical Cancer Research 24:23, pages 5841-5849.
Crossref
Crossref
Afsaneh Javadi, Vahab Nekoukar & Marzieh Ebrahimi. (2018) Modeling of Therapy-Induced Tumor Growth in Presence of Drug Resistance for Melanoma Cancer. Modeling of Therapy-Induced Tumor Growth in Presence of Drug Resistance for Melanoma Cancer.
Shinji Yamazaki. 2018. Early Drug Development. Early Drug Development
433
466
.
Jian Li, Rong Chen, Qing-yu Yao, Sheng-jun Liu, Xiu-yun Tian, Chun-yi Hao, Wei Lu & Tian-yan Zhou. (2017) Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model. Acta Pharmacologica Sinica 39:3, pages 472-481.
Crossref
Crossref
Jocelyn Gal, Gérard Milano, Jean-Marc Ferrero, Esma Saâda-Bouzid, Julien Viotti, Sylvie Chabaud, Paul Gougis, Christophe Le Tourneau, Renaud Schiappa, Agnes Paquet & Emmanuel Chamorey. (2017) Optimizing drug development in oncology by clinical trial simulation: Why and how?. Briefings in Bioinformatics.
Crossref
Crossref
Fabiano L. Ribeiro, Renato Vieira dos Santos & Angélica S. Mata. (2017) Fractal dimension and universality in avascular tumor growth. Physical Review E 95:4.
Crossref
Crossref
Fangran Hao, Siyuan Wang, Xiao Zhu, Junsheng Xue, Jingyun Li, Lijie Wang, Jian Li, Wei Lu & Tianyan Zhou. (2016) Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft. Pharmaceutical Research 34:2, pages 408-418.
Crossref
Crossref
N.V. Medvedeva, T.I. Torkhovskaya, L.V. Kostryukova, T.S. Zakharova, V.A. Kudinov, E.O. Kasatkina, V.N. Prozorovskiy & O.M. Ipatova. (2017) Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity. Biomeditsinskaya Khimiya 63:1, pages 56-61.
Crossref
Crossref
Kentaro Sakamaki, Yosuke Kito, Kentaro Yamazaki, Naoki Izawa, Takashi Tsuda, Satoshi Morita & Narikazu Boku. (2017) Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. ESMO Open 2:5, pages e000275.
Crossref
Crossref
Kenneth T. Luu & Joseph Boni. (2016) A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin. Cancer Chemotherapy and Pharmacology 78:4, pages 697-708.
Crossref
Crossref
Giulia Lestini, France Mentré & Paolo Magni. (2016) Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice. The AAPS Journal 18:5, pages 1233-1243.
Crossref
Crossref
Xi-wei Ji, Shuang-min Ji, Run-tao Li, Ke-hua Wu, Xiao Zhu, Wei Lu & Tian-yan Zhou. (2016) Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. Acta Pharmacologica Sinica 37:6, pages 825-833.
Crossref
Crossref
Melanie I. Titze, Otmar Schaaf, Marco H. Hofmann, Michael P. Sanderson, Stephan K. Zahn, Jens Quant & Thorsten Lehr. (2016) A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemotherapy and Pharmacology 77:6, pages 1303-1314.
Crossref
Crossref
Ana Ruiz-Garcia & Shinji Yamazaki. 2016. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development
121
150
.
Dean C. Bottino & Arijit Chakravarty. 2016. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development
209
235
.
Maria Luisa Sardu, Giuseppe De Nicolao & Italo Poggesi. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
391
413
.
Juan A. Delgado-SanMartin, Jennifer I. Hare, Alessandro P. S. de Moura & James W. T. Yates. (2015) Oxygen-Driven Tumour Growth Model: A Pathology-Relevant Mathematical Approach. PLOS Computational Biology 11:10, pages e1004550.
Crossref
Crossref
K Venkatakrishnan, LE Friberg, D Ouellet, JT Mettetal, A Stein, IF Trocóniz, R Bruno, N Mehrotra, J Gobburu & DR Mould. (2015) Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities. Clinical Pharmacology & Therapeutics 97:1, pages 37-54.
Crossref
Crossref
Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal & Paolo Vicini. (2014) Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. Journal of Pharmacology and Experimental Therapeutics 351:1, pages 67-76.
Crossref
Crossref
Sébastien Benzekry, Clare Lamont, Afshin Beheshti, Amanda Tracz, John M. L. Ebos, Lynn Hlatky & Philip Hahnfeldt. (2014) Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. PLoS Computational Biology 10:8, pages e1003800.
Crossref
Crossref
Tove Tuntland, Brian Ethell, Takatoshi Kosaka, Francesca Blasco, Richard Xu Zang, Monish Jain, Ty Gould & Keith Hoffmaster. (2014) Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Frontiers in Pharmacology 5.
Crossref
Crossref
B Ribba, NH Holford, P Magni, I Trocóniz, I Gueorguieva, P Girard, C Sarr, M Elishmereni, C Kloft & LE Friberg. (2014) A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis. CPT: Pharmacometrics & Systems Pharmacology 3:5, pages 1-10.
Crossref
Crossref
R Bruno, F Mercier & L Claret. (2014) Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials. Clinical Pharmacology & Therapeutics 95:4, pages 386-393.
Crossref
Crossref
Monica Simeoni, Paolo Magni, Italo Poggesi, Giuseppe De Nicolao & Maurizio Rocchetti. 2014. Modelling Methodology for Physiology and Medicine. Modelling Methodology for Physiology and Medicine
449
477
.
Mengyao Li, Hanqing Li, Xiaoliang Cheng, Xipei Wang, Liang Li, Tianyan Zhou & Wei Lu. (2013) Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine. Pharmaceutical Research 30:5, pages 1400-1408.
Crossref
Crossref
Ahmed Abbas Suleiman, Lucia Nogova & Uwe Fuhr. (2013) Modeling NSCLC Progression: Recent Advances and Opportunities Available. The AAPS Journal 15:2, pages 542-550.
Crossref
Crossref